Semaglutide vs. Tirzepatide: Are We Closing the Gap?

from Docs Who Lift · host Docs Who Lift

How the STEP-UP trial came to life, and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat’s coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Jul 24, 2025

Embed this episode

Attribution link and audio player

What this episode covers

Can higher doses of semaglutide really deliver better results, without the side effects? In this episode of Docs Who Lift, Dr. Spencer Nadolsky and Dr. Karl Nadolsky Jr. sit down with Canadian obesity expert and clinical trialist Dr. Sean Wharton to break down the latest data from the STEP-UP trial. They dig into the science behind tripling the dose of semaglutide, how it compares to drugs like tirzepatide, and what it means for the future of obesity treatment.